Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02650804 · ClinicalTrials.gov registry record · Phase 2
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 study, sponsored by BPGbio.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT02650804 is a Phase 2 study that has completed, run by BPGbio. The registered enrollment target is 45 participants.
The verdict
NCT02650804, a Phase 2 study, has completed, sponsored by BPGbio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of BPM31510 administered over 144-hours (two 72-hour 110mg/Kg doses) continuous intravenous (IV) infusion in combination with gemcitabine in advanced pancreatic cancer patients as 2nd / 3rd line therapy. The study will enroll up to 25 patients in the US and Europe.
Interventions
- DRUG Gemcitabine
- DRUG BPM31510 Nanosuspension Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2016-07-06 |
| Est. Completion | 2019-06-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02650804
The ClinicalTrials.gov registry entry for NCT02650804 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BPGbio, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT02650804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02650804 about?
NCT02650804 is a clinical study titled "BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients". This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of BPM31510 administered over 144-hours (two 72-hour 110mg/Kg doses) continuous intravenous (IV) infusion in combination with gemcitabine in advanced pancreatic cancer patients as 2nd / 3rd line t...
What is the current status of trial NCT02650804?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2016-07-06. Estimated completion is 2019-06-11.
What interventions are being tested in trial NCT02650804?
The interventions under investigation include: Gemcitabine (DRUG), BPM31510 Nanosuspension Injection (DRUG).
Who is sponsoring clinical trial NCT02650804?
This trial is sponsored by BPGbio, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.